The sale marks the first insider transaction by the biotech firm's CFO in over a year amid recent stock volatility. Travere Therapeutics CFO Jennifer Cline sold $115,368 worth of company stock, according to regulatory filings. The transaction involved 5,000 shares at an av
An Arcutis Biotherapeutics EVP offloaded $192k worth of stock, signaling potential insider sentiment shifts. Arcutis Biotherapeutics Executive Vice President Masaru Matsuda sold $192,000 in company stock, according to recent filings. The transaction involved a modest porti
Insider stock sale by company president may signal potential shifts in investor sentiment or corporate outlook. Ultra Clean Holdings President sold shares valued at $848,921, according to recent filings. The transaction reflects insider activity that often draws market att
The company reported a 700% year-over-year increase in AI-driven revenue, prompting an upward revision to annual guidance. Axon raised its full-year revenue and earnings guidance after first-quarter AI revenue surged 700% year-over-year. The company cited strong demand for
Equity markets surge as investors weigh potential easing of geopolitical tensions following Iran’s review of a US diplomatic proposal. Global stocks climbed to record levels as optimism grew over Iran’s review of a US diplomatic plan aimed at de-escalating tensions. Major
The automation firm’s record backlog signals strong demand, offsetting a quarterly earnings miss amid growth investments. Symbotic reported a $22.7 billion backlog for Q2 2026, a key driver of future revenue growth. The figure underscores robust demand for its warehouse au
UTI expects $905M-$915M revenue UTI has reaffirmed its fiscal year 2026 outlook, anticipating revenue between $905M and $915M. The company also expects earnings per share to range from $0.71 to $0.80. This outlook comes as new campuses ramp up, potentially
This central processing unit renaissance was confirmed when Intel reported earnings two weeks ago. AMD and now Arm told similar stories
The wireless connectivity firm expects non-GAAP earnings per share of $0.01 at the midpoint for the second quarter. Airgain projected second-quarter sales in the range of $12.5M to $14.5M, with a non-GAAP EPS midpoint of $0.01. The guidance reflects ongoing demand for its
Diagnostics firm Sera Prognostics reports a significant Q1 2026 revenue decline amid lower-than-expected test volumes and pricing pressure. Sera Prognostics posted a steep revenue decline in Q1 2026, driven by weaker demand for its prenatal diagnostic tests. The company ci
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.